The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Vincristine sulfate liposomes injection (VSLI) "bridging" to potentially curative hematopoietic stem cell transplantation (HSCT) in adults with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL).
G. J. Schiller
Research Funding - Talon Therapeutics
S. E. Coutre
No relevant relationships to disclose
M. L. Larson
No relevant relationships to disclose
D. Ben Yehuda
No relevant relationships to disclose
P. Venugopal
No relevant relationships to disclose
S. Goldberg
No relevant relationships to disclose
G. L. Messerschmidt
Employment or Leadership Position - Talon Therapeutics
Stock Ownership - Talon Therapeutics
J. Silverman
Employment or Leadership Position - Talon Therapeutics
Stock Ownership - Talon Therapeutics
S. R. Deitcher
Employment or Leadership Position - Talon Therapeutics
Stock Ownership - Talon Therapeutics
H. Kantarjian
No relevant relationships to disclose